Amrinone (CAS 60719-84-8) Supplier Information and Product Details

Amrinone is a positive inotropic agent used for short-term treatment of cardiac insufficiency that does not respond to treatment with other drugs. It is a selective cAMP phosphodiesterase (PDE 3) inhibitor with positive inotropic and vasodilatory activity. Amrinone increases the rate and force of heart contraction and may improve the prognosis in patients with congestive heart failure.

Frequently Asked Questions about Amrinone

Q: What is the main use of Amrinone?

A: Amrinone is primarily used for short-term treatment of cardiac insufficiency that does not respond to treatment with other drugs. It is effective in managing severe congestive heart failure, even in unresponsive, fully digitalized patients.

Q: How does Amrinone work?

A: Amrinone works as a selective cAMP phosphodiesterase (PDE 3) inhibitor. It increases the rate and force of heart contraction by inhibiting the enzyme responsible for breaking down cAMP, which plays a crucial role in regulating intracellular calcium levels in the heart.

Q: Are there any safety concerns with Amrinone?

A: Yes, Amrinone can be toxic if ingested or administered intravenously. It may cause cardiac arrhythmias, affect liver function, and lead to thrombocytopenia. It is also an experimental teratogen, meaning it could potentially cause birth defects. Always use under medical supervision.

Q: Has Amrinone's name been changed?

A: Yes, in 1999, the USP Nomenclature Committee and the United States Adopted Names (USAN) Council approved changing the nonproprietary name from amrinone to inamrinone. This change was made to avoid confusion with amiodarone, which had led to medication errors.